Quick Dispatch:
Your surmount studies tirzepatide SURMOUNT-2: Tirzepatide confers about 15% weight loss in adults with obesity and diabetes orders ship within 1-2 business days.
Delivery Options:
Order Tracking:
You'll receive a tracking link by email once your surmount studies tirzepatide SURMOUNT-2: Tirzepatide confers about 15% weight loss in adults with obesity and diabetes ships.
Need Help?
Questions about surmount studies tirzepatide SURMOUNT-2: Tirzepatide confers about 15% weight loss in adults with obesity and diabetes, sizing, or delivery? We're just an email away.
Live Shipping Estimates:
Enter your location at checkout to see available shipping methods and costs for surmount studies tirzepatide SURMOUNT-2: Tirzepatide confers about 15% weight loss in adults with obesity and diabetes in your area.
00377-2/asset/984f48c3-9a91-4eba-8a7d-d724f5e65288/main.assets/gr2_lrg.jpg)
Efficacy and safety of once-weekly tirzepatide in Japanese patients with obesity disease (SURMOUNT-J): a multicentre, randomised, double-blind, placebo-controlled phase 3 trial
23.69
Time to weight plateau with tirzepatide treatment in the SURMOUNT‐1 and SURMOUNT‐4 clinical trials - Horn - 2025 - Clinical Obesity
20.60
Effect of Tirzepatide on Maintenance of Weight Reduction
24.01
Tirzepatide and blood pressure reduction: stratified analyses of the SURMOUNT-1 randomised controlled trial
26.35
In the SURMOUNT-5 trial, Zepbound (tirzepatide) achieved a 20.2% average weight loss over 72 weeks, surpassing Wegovy (semaglutide)'s 13.7%. Additionally, 64.6% of Zepbound users lost at least 15% of their body weight,
24.01
ECO 2026: SURMOUNT-MAINTAIN proves tirzepatide sustains weight loss long term
29.23
In the SURMOUNT-4 trial, 82.5% of adults with obesity regained ≥25% of initial weight lost within one year of tirzepatide withdrawal; most showed reversal of cardiometabolic improvements. https://bit.ly/4rBMZgh
29.84
